RB1CC1 together with RB1 and p53 predicts long-term survival in Japanese breast cancer patients

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Chano, Tokuhiro ^a   Ikebuchi, Kaichiro ^a,b   Tomita, Yasuhiko ^c   Jin, Yufen ^c   Inaji, Hideo ^c   Ishitobi, Makoto ^c   Teramoto, Koji ^a   Ochi, Yasuko ^a,b   Tameno, Hitosuke ^a,b   Nishimura, Ichiro ^a   Minami, Kahori ^a   Inoue, Hirokazu ^a   Isono, Takahiro ^d   Saitoh, Masao ^d   Shimada, Taketoshi ^b   Hisa, Yasuo ^b   Okabe, Hidetoshi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; RETINOBLASTOMA 1 INDUCIBLE COILED COIL 1 PORTEIN; RETINOBLASTOMA 1 PROTEIN; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; PROTEIN TYROSINE KINASE; RB1CC1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ACCURACY; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; MAJOR CLINICAL STUDY; PHENOTYPE; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; ADULT; AGED; BIOSYNTHESIS; BREAST TUMOR; CELL NUCLEUS; COHORT ANALYSIS; GENE EXPRESSION REGULATION; GENETICS; JAPAN; METABOLISM; METHODOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL NUCLEUS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN-TYROSINE KINASES; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650995523     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015737     Document Type: Article

References (33)

1. Irvin WJ, Jr., Carey LA (2008) What is triple-negative breast cancer? Eur J Cancer 44: 2799-2805.
2. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, et al. (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7: 134.
3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. (2007) Triplenegative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434.
4. Borg A, Zhang QX, Alm P, Olsson H, Sellberg G (1992) The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression. Cancer Res 52: 2991-2994.
5. Ceccarelli C, Santini D, Chieco P, Taffurelli M, Gamberini M, et al. (1998) Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile. J Clin Pathol 51: 818-824.
6. Derenzini M, Montanaro L, Vici M, Barbieri S, Ceccarelli C, et al. (2007) Relationship between the RB1 mRNA level and the expression of phosphor- ylated RB protein in human breast cancers: their relevance in cell proliferation activity and patient clinical outcome. Histol Histopathol 22: 505-513.
7. Giacinti C, Giordano A (2006) RB and cell cycle progression. Oncogene 25: 5220-5227.
8. Chano T, Ikegawa S, Kontani K, Okabe H, Baldini N, et al. (2002) Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells. Oncogene 21: 1295-1298.
9. Chano T, Kontani K, Teramoto K, Okabe H, Ikegawa S (2002) Truncating mutations of RB1CC1 in human breast cancer. Nat Genet 31: 285-288.
10. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, et al. (2003) From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 100: 7737-7742.
11. Melkoumian ZK, Peng X, Gan B, Wu X, Guan JL (2005) Mechanism of cell cycle regulation by FIP200 in human breast cancer cells. Cancer Res 65: 6676-6684.
12. Gan B, Melkoumian ZK, Wu X, Guan KL, Guan JL (2005) Identification of FIP200 interaction with the TSC1-TSC2 complex and its role in regulation of cell size control. J Cell Biol 170: 379-389.
13. Chano T, Saji M, Inoue H, Minami K, Kobayashi T, et al. (2006) Neuromuscular abundance of RB1CC1 contributes to the non-proliferating enlarged cell phenotype through both RB1 maintenance and TSC1 degradation. Int J Mol Med 18: 425-432.
14. Gan B, Peng X, Nagy T, Alcaraz A, Gu H, et al. (2006) Role of FIP200 in cardiac and liver development and its regulation of TNFalpha and TSC-mTOR signaling pathways. J Cell Biol 175: 121-133.
15. Gan B, Guan JL (2008) FIP200, a key signaling node to coordinately regulate various cellular processes. Cell Signal 20: 787-794.
16. Hara T, Takamura A, Kishi C, Iemura S, Natsume T, et al. (2008) FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells. J Cell Biol 181: 497-510.
17. Hara T, Mizushima N (2009) Role of ULK-FIP200 complex in mammalian autophagy: FIP200, a counterpart of yeast Atg17? Autophagy 5: 85-87.
18. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, et al. (2009) Nutrientdependent mTORC1 Association with the ULK1-Atg13-FIP200 Complex Required for Autophagy. Mol Biol Cell 20: 1981-1991.
19. Ikubuchi K, Chano T, Ochi Y, Tameno H, Shimada T, et al. (2009) RB1CC1 activates the promoter and expression of RB1 in human cancer. Int J Cancer 125: 861-867.
20. Chano T, Ikebuchi K, Ochi Y, Tameno H, Tomita Y, et al. (2010) RB1CC1 activates RB1 pathway and inhibits proliferation and cologenic survival in human cancer. PLoS One 5: e11404.
21. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, et al. (2003) Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 112: 1809-1820.
22. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, et al. (1999) Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402: 672-676.
23. Balik S, Kimchi A (2008) Autophagy and tumor suppression: recent advances in understanding the link between autophagic cell death pathways and tumor development. Adv Exp Med Biol 615: 177-200.
24. Mathew R, Karantza-Wadsworth V, White E (2007) Role of autophagy in cancer. Nat Rev Cancer 7: 961-967.
25. Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, et al. (2009) Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta.
26. Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, et al. (2009) Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ 16: 87-93.
27. Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132: 27-42.
28. Young AR, Narita M, Ferreira M, Kirschner K, Sadaie M, et al. (2009) Autophagy mediates the mitotic senescence transition. Genes Dev 23: 798-803.
29. Martin N, Schwamborn K, Urlaub H, Gan B, Guan JL, et al. (2008) Spatial interplay between PIASy and FIP200 in the regulation of signal transduction and transcriptional activity. Mol Cell Biol 28: 2771-2781.
30. Mersin H, Yildirim E, Berberoglu U, Gulben K (2008) The prognostic importance of triple negative breast carcinoma. Breast 17: 341-346.
31. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109: 1721-1728.
32. Elledge RM, Allred DC (1998) Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 52: 79-98.
33. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312.